2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor
  5. DP Isoform
  6. DP Inhibitor

DP Inhibitor

DP Inhibitors (7):

Cat. No. Product Name Effect Purity
  • HY-B0195
    Tranilast
    		Inhibitor 99.57%
    Tranilast (MK-341) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
  • HY-13448
    Nedocromil
    		Inhibitor 98.02%
    Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
  • HY-109134
    Pizuglanstat
    		Inhibitor 99.40%
    Pizuglanstat (compound 3) is a prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthases (H-PGDS). Pizuglanstat can be used for myodegenerative disease research, such as muscular dystrophy.
  • HY-U00027
    Quinotolast sodium
    		Inhibitor 98.12%
    Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits histamine, LTC4 and PGD2 release in a concentration-dependent manner.
  • HY-16344
    Nedocromil sodium
    		Inhibitor
    Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
  • HY-B0195A
    Tranilast sodium
    		Inhibitor
    Tranilast sodium (MK-341 sodium) acts as an anti-atopic agent. Tranilast suppresses production of prostaglandin D2 (PGD2, IC50= 0.1 mM). Tranilast sodium exhibits anti-inflammatory and immunomodulatory effects. Tranilast sodium antagonizes angiotensin II and inhibits its biological effects in vascular smooth muscle cells.
  • HY-100441S1
    Treprostinil-13C2,d
    		Inhibitor
    Treprostinil-13C2,d is the 13C- and deuterium labeled Treprostinil. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.